Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE? - Scorecard - MDSpire

Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?

  • By

  • Zhuo Li

  • Jie Tan

  • Zhi-Jun Li

  • Peng Yan

  • Hua Xiang

  • May 1, 2026

  • 0 min

Share

Clinical Scorecard: Enhancing the Efficacy of TACE in Intermediate and Advanced Hepatocellular Carcinoma: The Role of Systemic Therapy Integration

At a Glance

CategoryDetail
Condition
Key MechanismsTransarterial chemoembolization (TACE) combined with systemic therapies (targeted agents, immune checkpoint inhibitors) may improve overall survival in specific patient populations.
Target Population
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor progression-free survival (PFS), overall survival (OS), and adverse events (AEs).
      • Assess treatment response using mRECIST criteria.

      Risks

        Patient & Prescribing Data

        Combination therapy may enhance OS in BCLC-C patients without significantly increasing adverse events; however, careful monitoring for AEs is essential.

        Clinical Best Practices

        • practice_1

        References

        Original Source(s)

        Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?

        • by Zhuo Li, Jie Tan, Zhi-Jun Li, Peng Yan, Hua Xiang

        • May 1, 2026

        Related Content

        FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

        Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

        Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report